Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Evidence on Acute Myocardial Infarctions in Japan Compiled by Korosho Study Group
May 14, 2001
- Wholesalers' FTC to Stop Members Supporting Medical Institution Social Gatherings
May 14, 2001
- Diagnostic, Treatment GL for Urinary Incontinence in Women Prepared
May 14, 2001
- BUSINESS NEWS IN BRIEF -2-
May 14, 2001
- Health Insurance Coverage for Viagra Demanded by the Public: Pfizer Seminar
May 14, 2001
- Kyowa Hakko Kogyo Aims at \300 Bil. Drug Sales in 2011: President Hirata
May 14, 2001
- 2hPG Recommended for Predicting Cardiovascular Disease Mortality: Takeda Seminar
May 14, 2001
- NBI to Increase Its Sales to \110 Bil. in 2004: President Kawabata
May 14, 2001
- GLs on Proper Use of Antibacterials Completed
May 14, 2001
- Eisai Ties Up with Neurogenetics
May 14, 2001
- OTC NEWS IN BRIEF
May 14, 2001
- BUSINESS NEWS IN BRIEF -1-
May 14, 2001
- Sumitomo Corp. Establishes Bioventure Investment Fund
May 14, 2001
- DIAGNOSTIC NEWS IN BRIEF
May 14, 2001
- Rohto to Launch Obagi Series of Skin Care Products in Japan
May 14, 2001
- MEDICAL DEVICE NEWS IN BRIEF
May 14, 2001
- WORLD NEWS IN BREF
May 14, 2001
- Japan-EU Mutual GMP Recognition Accord to Be Approved by Diet
May 14, 2001
- 6 New Drugs Including Insulin-lyspro Approved
May 14, 2001
- Chugai Starts V's 21 Plan: President Nagayama
May 14, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…